البروبرانولول والأورام الوعائية الطفلية: دراسة تجريبية عشوائية.

Authors

  • فوز حسن
  • غزل ديب
  • زين اسحق

Abstract

Background: Hemangiomas are the most common benign vascular tumors of infancy. Although most infantile hemangiomas (IHs) have the ability to involute spontaneously after initial proliferation and resolve without consequence, intervention is required in a subset of IHs, which develop complications resulting in ulceration, bleeding, or aesthetic deformity. The primary treatment for this subset of IHs is pharmacological intervention, and propranolol has become the new first-line treatment for complicated hemangiomas.

Objects: To assess propranolol efficacy and safety in complicated infantile hemangiomas

in two different age groups.

 

Patients & methods: We report on 30 infants with infantile hemangiomas, age (1-84) months,  treated with oral propranolol 2 mg \ kg \ day  at different ages for a period of six months.

Inclusion criteria were all patients with infantile hemangioma at ages from 1 month who had \ had not received any previous therapy.

The evolution of all hemangiomas since baseline (pre-therapy) until the end of follow-up was assessed on the basis of clinical features (color, palpable softening, and size ) and taken at follow up visits by two different physicians .

Results: Our results showed that propranolol was effective in arresting the proliferative

phase and in accelerating the involution of infantile hemangiomas in 93.3 % of cases.

Propranolol efficacy was clear even when it was started after 12 months of life. bronchospasm was the most common side effect and was moderate to severe which indicated cessation of the treatment for three days in some case[1]

Conclusion: Propranolol hydrochloride at a dose of 2 mg \ kg \ day  is effective  in treating infantile hemangioma.

ضمت هذه الدراسة عيّنة من 30 طفلاً تراوحت أعمارهم بين شهر واحد و7 سنوات، مصابين بأورام وعائية طفلية، وتوزعوا على مجموعتين عمريتين. تمت معالجتهم بالبروبرانولول الفموي بجرعة 2 ملغ \ كغ \ اليوم لمدة ستة أشهر. معايير الاشتمال تمثلت بجميع الأطفال المصابين بالأورام الوعائية الطفلية ممن تلقوا أو لم يتلقوا علاجات سابقة.

قيمت فعالية العلاج من خلال الفحص السريري للأورام (اللون, القياس, الملمس) من قبل طبيبين غير الطبيب الفاحص الأساسي, وأُخذت الصور الفوتوغرافية عند كل زيارة.

وجدنا أن البروبرانولول الفموي بجرعة 2 ملغ \ كغ \ اليوم تمكن من إيقاف النمو الورمي وتسريع التراجع عند 93.3% من الحالات حتى عند الأطفال بعمر أكبر من سنة.

التشنج القصبي هو أشيع الآثار الجانبية, تراوح بين متوسط وشديد اضطرنا أحياناً لإيقاف العلاج لمدة لم تتجاوز الثلاث أيام غالباً.

Downloads

Published

2019-11-03

How to Cite

1.
حسن ف, ديب غ, اسحق ز. البروبرانولول والأورام الوعائية الطفلية: دراسة تجريبية عشوائية. Tuj-hlth [Internet]. 2019Nov.3 [cited 2024Nov.24];41(5). Available from: https://journal.tishreen.edu.sy/index.php/hlthscnc/article/view/9142

Issue

Vol. 41 No. 5 (2019): العلوم الصحية

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

 Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series   .  The Readers have the right to send, print and subscribe to the initial version of the article, and the title of  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series  Publisher

journal uses a CC BY-NC-SA license which mean

You are free to:

  • Adapt — remix, transform, and build upon the material
  •  
  • The licensor cannot revoke these freedoms as long as you follow the license terms.

 

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Most read articles by the same author(s)

1 2 3 > >>